Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue 1, 2009, Pages 41-49

  Weinstein, Doron ^a   Simon, Meital ^a   Yehezkel, Einat ^a   Laron, Zvi ^b   Werner, Haim ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Detemir; Glargine; Insulin; Insulin analogues; Insulin like growth factor I; Lispro

Indexed keywords

INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; DRUG DERIVATIVE; GLARGINE; INSULIN;

APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CARCINOGENIC ACTIVITY; CELL ACTIVITY; CELL COUNT; CELL CULTURE; CELL PROLIFERATION; CELL PROTECTION; COLORECTAL CANCER; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ADENOCARCINOMA; BREAST TUMOR; CELL DIVISION; COLORECTAL TUMOR; DOSE RESPONSE; DRUG EFFECT; FEMALE; MALE; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL CULTURE; TUMOR CELL LINE;

ADENOCARCINOMA; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MALE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 65549138380     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.912     Document Type: Article

References (30)

1. Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev 2001; 22: 706-717.
2. Hirsch IB. Insulin analogues. N Engl J Med 2005; 352: 174-183.
3. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001; 358: 739-746.
4. Gupta K, Krishnaswamy G, Karnad A, Peiris AN. Insulin: a novel factor in carcinogenesis. Am J Med Sci 2002; 323: 140-145.
5. Stammberger I, Bube A, Durchfeld-Meyer B, Donnaubauer H, Troschau G. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 2002; 21: 171-179.
6. Bornfeldt KE, Gidlof RA, Wasteson A, et al. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 1991; 34: 307-313.
7. Slieker LJ, Brooke GS, DiMarchi RD, et al. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 1997; 40: S54-S61.
8. Werner H, Weinstein D, Bentov I. Similarities and differences between insulin and IGF-I: structures, receptors, and signaling pathways. Arch Physiol Biochem 2008; 114: 17-22.
9. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT, Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143-163.
10. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res 1999; 253: 1-6.
11. Werner H, Maor S. The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action. Trends Endocrinol Metab 2006; 17: 236-242.
12. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
13. Laron Z. Insulin-like growth factor-1: a growth hormone. Mol Pathol 2001; 54: 311-316.
14. Laron Z. IGF-1 and insulin as growth hormones. In Biology of IGF-1: Its Interaction with Insulin in Health and Malignant States, LeRoith D, Goode J, Bock G (eds). John Wiley and Sons: Chichester, 2004; 58-63.
15. Bahr MT, Kolter G, Seipke G, Eckel J. Growth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31, ArgB32] insulin (HOE 901) in muscle cells. Eur J Pharmacol 1997; 320: 259-265.
16. Eckardt K, May C, Koenen M, Eckel J. IGF-I receptor signalling determines themitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 2007; 50: 2534-2543.
17. Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-1501.
18. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 20-47.
19. Zick Y. Molecular basis of insulin action. Novartis Found Symp 2004; 262: 36-50.
20. Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996; 68: 183-223.
21. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003; 107: 873-877.
22. Nam RK, Trachtenberg J, Jewett MA, et al. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 1270-1273.
23. Giovannucci E, Pollak MN, Platz EA, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000; 9: 345-349.
24. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factors. Proc Nutr Soc 2001; 60: 91-106.
25. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253: 2769-2776.
26. Dupont J, LeRoith D. Insulin and insulin-like growth factor-I receptors: similarities and differences in signal transduction. Horm Res 2001; 55(Suppl. 2): 22-26.
27. Staiger K, Hennige AM, Staiger H, Haring H-U, Kellerer M. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 2007; 39: 65-67.
28. Cianfarani S, Tedeschi B, Germani D, et al. In vitro effects of growth hormone (GH) and insulin-like growth factor I and II (IGF-I and -II) on chromosome fragility and p53 protein expression in human lymphocytes. Eur J Clin Invest 1998; 28: 41-47.
29. Bentov I, Werner H. IGF, IGF receptor and overgrowth syndromes. Pediatr Endocrinol Rev 2004; 1: 352-360.
30. Staiger K, Staiger H, Schweitzer MA, et al. Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia 2005; 48: 1898-1905.